Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time: Editorial comment

Samir S. Taneja

doi:10.1016/j.juro.2014.05.077

Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time: Editorial comment

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	421-422
Number of pages	2
Journal	Journal of Urology
Volume	192
Issue number	2
DOIs	https://doi.org/10.1016/j.juro.2014.05.077
State	Published - Aug 2014

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2014.05.077

Cite this

@article{72b6f9a05232478a865be729b989bd26,

title = "Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time: Editorial comment",

author = "Taneja, {Samir S.}",

year = "2014",

month = aug,

doi = "10.1016/j.juro.2014.05.077",

language = "English (US)",

volume = "192",

pages = "421--422",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Re

T2 - Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time: Editorial comment

AU - Taneja, Samir S.

PY - 2014/8

Y1 - 2014/8

UR - http://www.scopus.com/inward/record.url?scp=84904214933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904214933&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2014.05.077

DO - 10.1016/j.juro.2014.05.077

M3 - Comment/debate

C2 - 25034990

AN - SCOPUS:84904214933

SN - 0022-5347

VL - 192

SP - 421

EP - 422

JO - Journal of Urology

JF - Journal of Urology

IS - 2

ER -

Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time: Editorial comment

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this